Peter Harrison

Plasma p-tau212 identifies cognitively unimpaired individuals with emerging amyloid-ß pathology

Przemysław R. Kac, Armand González Escalante, Marta Milà Alomà, Nicholas J. Ashton et autres

Clinical Validation of Novel Immunoassays for Plasma Phosphorylated Tau 217, 212, 181, 231, and Brain‐Derived Tau Across the Biochemical Spectrum of Alzheimer's Disease

Maciej Dulewicz, Przemysław R. Kac, Fernando C. Ortíz, Thomas K. Karikari et autres

Plasma biomarkers have emerged as promising less invasive alternatives for Alzheimer's disease (AD) detection. However, the diagnostic performance of phosphorylated tau (p-tau) isoforms remains incompletely validated. In a cohort of 160 patients from a memory clinic, plasma levels of p-tau217, p-tau212, p-tau181, …

se, pl, gb, de, us, cn, fr (code pays fourni par la source)

Author response for "Clinical validation of novel immunoassays for plasma phospohorylated tau 217, 212, 181, 231 and brain-derivied tau across the biochemical spectrum of Alzheimer’s Disease"

Maciej Dulewicz, Przemysław R. Kac, Fernando C. Ortíz, Thomas K. Karikari et autres

Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease

Fernando González‐Ortiz, Bjørn‐Eivind Kirsebom, Yara Yakoub, J Gundersen et autres

BACKGROUND AND OBJECTIVES: Aligning biomarker evidence with clinical presentation in early Alzheimer disease (AD) is essential for improving diagnosis, prognosis, and interventions. This study evaluates the relationship between cognitive impairment, future decline, and phosphorylated tau levels in plasma and CSF in predementia …

se, no, ca, gb, us, cn, fr (code pays fourni par la source)

Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity

Bjørn‐Eivind Kirsebom, Fernando González‐Ortiz, Sinthujah Vigneswaran, Geir Bråthen et autres

INTRODUCTION: Heterogeneity of clinical progression in Alzheimer's disease (AD) complicates the assessment of disease progression and treatment effects in trials. This study evaluates the potential of plasma phosphorylated tau-217 (p-tau217) to capture this heterogeneity. METHODS: We used k-means clustering to analyze cognitive …

no, se, nl, gb, cn, fr (code pays fourni par la source)

Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease

Przemysław R. Kac, Daniel Alcolea, Laia Montoliu‐Gaya, Susana Fernández et autres

BACKGROUND: All individuals with Down syndrome (DS) will develop full-blown Alzheimer´s disease (AD) pathology by age 40. Several genes encoded in chromosome 21, including dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), have been proven to contribute to the pathology. Phosphorylation of tau at …

se, es, gb, no, us, cn, fr (code pays fourni par la source)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia

Cassandra Marotta, Fernando González‐Ortiz, Michael Turton, Henrik Zetterberg et autres

Abstract INTRODUCTION Brain‐derived tau (BD‐tau) measures tau specifically from brain‐derived sources and can differentiate Alzheimer's disease (AD) from other diseases. This study investigated BD‐tau as a potential biomarker of treatment effect. METHODS BD‐tau and phosphorylated tau‐217 (p‐tau217) levels were measured after treatment …

au, se, gb, hk (code pays fourni par la source)

The potential dual role of tau phosphorylation: plasma phosphorylated-tau217 in newborns and Alzheimer’s disease

Fernando González‐Ortiz, Jakub Vávra, Emma Payne, Bjørn‐Eivind Kirsebom et autres

Abstract Tau phosphorylation plays an important role in brain physiology and pathology. During foetal development, it supports microtubule dynamics and neuroplasticity, whereas in Alzheimer’s disease (AD), it drives pathological tau aggregation and tangle formation. In this multicentre study (n = 462), we …

se, us, au, in, no, es, gb, de, cn, fr (code pays fourni par la source)

Different phosphorylated tau isoforms in biochemical diagnosis of Alzheimer’s disease

Maciej Dulewicz, Przemysław R. Kac, Fernando González‐Ortiz, Thomas K. Karikari et autres

Abstract Background In the context of Alzheimer's disease (AD), blood‐based biomarkers have become increasingly important for various clinical purposes, such as screening patients and tracking the progression of the disease. Tau is a protein that stabilizes microtubules in nerve cells. In AD, …

se, us, pl, de, gb (code pays fourni par la source)

Elevated levels of CSF p‐tau212 in FTLD‐Tau

Przemysław R. Kac, Katheryn A Q Cousins, Leslie M. Shaw, David J. Irwin et autres

Abstract Background Phosphorylated‐tau (p‐tau) biomarkers are typically specific for Alzheimer’s disease (AD) and are less elevated in the cerebrospinal fluid (CSF) of frontotemporal lobar degeneration (FTLD) type tau (FTLD‐tau). FTLD is a pathologically and clinically heterogenous neurodegenerative disorder, and we currently lack …

se, us, gb (code pays fourni par la source)

Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer’s disease

Przemysław R. Kac, Daniel Alcolea, Laia Montoliu‐Gaya, Susana Fernández et autres

Background: All individuals with Down Syndrome (DS) will develop full-blown Alzheimeŕs disease (AD) pathology by age 40, decades before the occurrence of sporadic late-onset AD. Understanding this strong biological relation between age and AD pathology risk in DS is important to accelerate …

se, es, gb, no, us, cn, fr (code pays fourni par la source)

Impact of clinical severity on plasma p-tau performance in predementia Alzheimer’s disease

Fernando González‐Ortiz, Bjørn‐Eivind Kirsebom, Yara Yakoub, J Gundersen et autres

Abstract Background and objectives Detecting Alzheimer’s disease (AD) biological and clinical changes is crucial for early diagnostic and therapeutic interventions. Here we investigate the relationship between clinical severity and levels of phosphorylated tau, focusing on plasma biomarkers, in preclinical and prodromal AD. …

se, no, ca, gb, us, cn, fr (code pays fourni par la source)